Back to Search Start Over

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients

Authors :
Sara Galimberti
Carlo Gambacorti Passerini
Marianna Greco
Federica Orru
Claudia Labate
Bruno Martino
Giuseppe Delogu
Claudio Fozza
Giovanni Caocci
Giorgio La Nasa
Christian Secchi
Elisabetta Abruzzese
Francesco Galimi
Malgorzata Monika Trawinska
Caocci, G
Greco, M
Delogu, G
Secchi, C
Martino, B
Labate, C
Abruzzese, E
Trawinska, M
Galimberti, S
Orru, F
Fozza, C
GAMBACORTI PASSERINI, C
Galimi, F
La Nasa, G
Source :
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-3 (2016), Journal of Hematology & Oncology
Publication Year :
2016
Publisher :
BMC, 2016.

Abstract

We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR as the telomere to single copy gene (36B4) ratio normalized to a reference sample (K-562 DNA). Age-corrected RTL (acRTL) was also obtained. The 36-month probability of treatment-free remission (TFR) was 59.4 %. TFR patients showed shorter acRTL compared to relapsed (mean ± SD = 0.01 ± 0.14 vs 0.20 ± 0.21; p = 0.01). TFR was significantly higher in CML patients with acRTL ≤0.09 (78.9 vs 30.8 %, p = 0.002). CML stem cells harboring longer telomeres possibly maintain a proliferative potential after treatment discontinuation. Electronic supplementary material The online version of this article (doi:10.1186/s13045-016-0293-y) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
17568722
Volume :
9
Issue :
1
Database :
OpenAIRE
Journal :
Journal of Hematology & Oncology
Accession number :
edsair.doi.dedup.....2f72fb763a29efefb374e5036d2c25da
Full Text :
https://doi.org/10.1186/s13045-016-0293-y